

- **Name:** Jin Won Kim
 - **Current Position & Affiliation:** Associate Professor
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine
 - **Country:** Republic of Korea
-

• Educational Background:

- March 1997 – Feb. 2003: M.D. with Honor, Pusan National University College of Medicine, Pusan, Korea
- Sept. 2005 – Feb. 2008: M.Sc., Molecular Oncology, Department of Medicine, Graduate School, Seoul National University, Seoul, Korea
- Sept. 2011 – February 2017: Ph.D., (PhD. at February 2017), Molecular Oncology, Department of Medicine, Graduate School, Seoul National University, Seoul, Korea

Postgraduate training:

- March 2003 – Feb. 2004: Internship Course, Seoul Asan Medical Center, Seoul, Korea
- March 2004 – Feb. 2008: Resident Course, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- May 2008 – April 2011: Public health doctor, Ministry of Justice
- May 2011 – Feb. 2012: Clinical fellowship course, Division of Medical Oncology-Hematology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

• Professional Experience:

- March 2018 – Present: Associate Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine
- March 2012 – February 2018: Assistant Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine

• Professional Organizations:

- American Society of Clinical Oncology
- American Association for Cancer Research
- Korean Medical Association
- Korean Internal Medicine
- Korean Cancer Study Group
- Korean Cancer Association
- Korean Association for Clinical Oncology
- Korean GIST Study Group

• **Main Scientific Publications:**

1. **Kim JW**, Cho SY, Chae J, Kim JW, Kim TY, Lee KW, Oh DY, Bang YJ, Im SA. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. *Cancer Res Treat.* 2020 Oct;52(4):1178-1187. doi: 10.4143/crt.2020.313. Epub 2020 Jun 11.
2. **Kim JW**, Min A, Im SA, Jang H, Kim YJ, Kim HJ, Lee KH, Kim TY, Lee KW, Oh DY, Kim JH, Bang YJ. TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy. *Cancers (Basel).* 2020 Feb 3;12(2):334. doi: 10.3390/cancers12020334.
3. **Kim JW**, Han SW, Cho JY, Chung IJ, Kim JG, Lee KH, Park KU, Baek SK, Oh SC, Lee MA, Oh D, Shim B, Ahn JB, Shin D, Lee JW, Kim YH. Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. *Eur J Cancer.* 2020 May;130:51-62. doi: 10.1016/j.ejca.2020.02.018. Epub 2020 Mar 13.
4. Choi IS, Kim KH, Lee JH, Suh KJ, Kim JW, Park JH, Kim YJ, Kim JS, Kim JH, **Kim JW**. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. *Eur J Cancer.* 2021 Sep;154:288-295. (**corresponding author**)
5. **Kim JW**, Lee KH, Kim JW, Suh KJ, Nam AR, Bang JH, Jin MH, Oh KS, Kim JM, Kim TY, Oh DY. The prognostic role of soluble transforming growth factor-beta and its correlation with soluble programmed death-ligand 1 in biliary tract cancer. *Liver Int.* 2021 Feb;41(2):388-395. doi: 10.1111/liv.14636.
6. Suh KJ, **Kim JW**, Kim JE, Sung JH, Koh J, Kim KJ, Kim JW, Ahn SH, Park DJ, Kim HH, Lee HS, Lee KW. Correlation between tumor infiltrating immune cells and peripheral regulatory T cell determined using methylation analyses and its prognostic significance in resected gastric cancer. *PLoS One.* 2021 Jun 4;16(6):e0252480. doi: 10.1371/journal.pone.0252480. eCollection 2021. (**corresponding author**)
7. Suh KJ, Yoon S, **Kim JW**, Yoon SH, Kim JW, Kim SH, Kim YJ, Lee KW, Lee JS, Kim JH. A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy. *J Geriatr Oncol.* 2021 Jul;12(6):922-929. doi: 10.1016/j.jgo.2021.02.018. Epub 2021 Feb 26. (**corresponding author**)
8. Kang SH, Min SH, **Kim JW**, Lee E, Park SW, Lee S, Oh HJ, Park YS, Lee YJ, Kim JW, Ahn SH, Suh YS, Lee KW, Lee HS, Kim HH. Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis. *Ann Surg Oncol.* 2022 Aug;29(8):5084-5091. (**corresponding author**)
9. Jung K, Lee S, Na HY, Kim JW, Lee JC, Hwang JH, **Kim JW**, Kim J. NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer. *Sci Rep.* 2022 Dec 3;12(1):20937. (**corresponding author**)